| Literature DB >> 31085965 |
Hee Kyung Kim1, Weon Jin Ko1, Chang-Il Kwon1, Ga Won Song1, In Kyun Yoo1, Ji Hyun Song1, Hak Su Kim1, Joo Young Cho1.
Abstract
Endoscopic submucosal dissection is recommended as an alternative therapy for early esophageal cancer. However, achieving curative resection in this procedure remains controversial since precise prediction of lymph node metastasis can be difficult. Here, we present the preliminary results of endoscopic submucosal dissection followed by concurrent chemoradiotherapy for early esophageal cancer with a high risk of lymph node metastasis. From May 2006 to January 2014, six patients underwent concurrent chemoradiotherapy after endoscopic submucosal dissection with a median follow-up period of 63 months. No complications were encountered during concurrent chemoradiotherapy. Although local recurrence did not occur in all patients, two patients were diagnosed with metachronous cancer. Overall, the survival rate was 100%. Thus, endoscopic submucosal dissection followed by concurrent chemoradiotherapy may be a feasible treatment for early esophageal cancer in patients with a high risk of lymph node metastasis. Future prospective large-scale studies are warranted to confirm our results.Entities:
Keywords: Concurrent chemoradiotherapy; Early esophageal cancer; Endoscopic submucosal dissection
Year: 2019 PMID: 31085965 PMCID: PMC6785410 DOI: 10.5946/ce.2018.176
Source DB: PubMed Journal: Clin Endosc ISSN: 2234-2400
Fig. 1.(A) A flat elevated mucosal lesion, 2.5–3.0 cm in size and located 20–23 cm from the upper incisor, was detected during an esophagogastroduodenoscopy; (B) Magnification endoscopy revealed dilatation and irregular caliber changes of the intrapapillary capillary loop (IPCL-V1); (C) ESD was performed based on the biopsy results that suggested the presence of squamous cell carcinoma; (D) The specimen was 22×13 mm in size.
Six Cases of Concurrent Chemoradiotherapy after ESD for the Treatment of Superficial Esophageal Cancer
| No. | Date of diagnosis | Age/Sex | Location of tumor (from U.I) | Pre-ESD diagnosis | ESD results | Progress | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Diagnosis | Size (mm) | Depth of invasion | Resection margin | Lymphatic invasion | Vascular invasion | Follow-up period (mo) | Recurrence | |||||
| 1 | 2006-09 | 58/M | 20 cm | SqCC, MD | SqCC, MD | 22×13 | M3 | Free | Positive | Negative | 124 | No |
| 2 | 2010-07 | 61/M | 25 cm | SqCC, WD | SqCC, WD | 27×23 | SM3;450 μm | Free | Negative | Negative | 66 | No |
| 3 | 2010-10 | 69/F | 32 cm | SqCC, WD | SqCC, WD | 25×18 | M2 | Free | Positive | Negative | 75 | No |
| 4 | 2012-01 | 55/M | 32 cm | SqCC, WD | SqCC, WD | 22×41 | M2 | Free | Positive | Negative | 60 | No |
| 5 | 2014-01 | 65/M | 28 cm | SqCC, MD | SqCC, MD | 42×22 | SM1;150 μm | Free | Positive | Negative | 30 | No |
| 6 | 2014-07 | 67/M | 32 cm | SqCC, MD | SqCC, MD | 25×13 | M3 | Free | Positive | Negative | 29 | No |
ESD, endoscopic submucosal dissection; M, mucosa; MD, moderately-differentiated; SM, submucosa; SqCC, squamous cell carcinoma; U.I, upper incisor; WD, well-differentiated.
Patient Comorbidities
| Patient no. | Date of diagnosis | Age/Diagnosis | |
|---|---|---|---|
| 1 | 2006-09 | 58/M | Duodenal ulcer |
| 2 | 2010-07 | 61/M | Hypertension, chronic kidney disease |
| 3 | 2010-10 | 69/F | Early gastric cancer, laryngeal cancer, hypertension, cerebral infarction |
| 4 | 2012-01 | 55/M | Diabetes |
| 5 | 2014-01 | 65/M | Hypertension, benign prostate hypertrophy |
| 6 | 2014-07 | 67/M | None |
Fig. 2.Cancer-invaded submucosal layer of Patients 2 and 5 are shown in panels (A) and (B), respectively.